ACS Flashcards

(25 cards)

1
Q

Difference between NSTEMI and UA

A

severity of ischemia. NSTEMI has positive biomarkers and UA does not

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ECG suggesting NSTEMI/UA

A

ST depression, T wave inversion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ECG suggesting STEMI

A

ST elevation; left bundle branch block

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Door to balloon time of _________ or less for patients undergoing PCI for STEMI

A

90 minutes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

P2Y-12 inhibitor contraindicated in patients with any history of stroke or TIA because of bleeding risk

A

Prasugrel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Prasugrel has a warning of use in patients > ______ years old and < _______kg

A

> 75 yo

<60 kg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which P2Y12 inhibitor is given IV?

A

Cangrelor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which P2Y12 inhibitor(s) should held 5 days prior to CABG

A

Clopidogrel

TIcagrelor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which P2Y12 inhibitor(s) should be held for 7 days prior to CABG

A

Prasugrel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Avoid concomitant maintenance dose of aspirin >100mg due to lack of efficacy with this P2Y12 inhibitor

A

Ticagrelor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Clopidogrel LD and MD

A

LD: 300-600mg
MD: 75mg QD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Prasugrel LD & MD

A

LD: 60mg
MD: 5-10mg QD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Ticagrelor LD & MD

A

LD: 180mg
MD: 90 mg BID

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which p2Y12 inhibitor is not recommended as an inhitial antiplatelet therapy before PCI and why

A

prasugrel

increase in bleeding (CABG, non-CABG and life-threatening)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Common adverse effect with ticagrelor

A

dyspnea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Duration of clopidogrel/prasugrel/or ticagrelor after PCI with BMS or DES

A

ideally >= 12 months

HIgh bleeding risk (OAC or increased risk severe bleeding complications like major intracranial surgery) less than 12 months is suggested

17
Q

Antiplatelet after CABG

A

DAPT to complete 1 year

18
Q

Antiplatelet after fibrinolytic (STEMI)

A

Minimum 14 days; ideally >=12 months with clopidogrel

19
Q

Antiplatelet after medical therapy (no revascularization)

A

> =12 months (clopidogrel or ticagrelor)

20
Q

Switching from ticagrelor or prasugrel to clopidogrel

A

Take clopidogrel 600mg LD 24 hours after last dose.

COnsider starting with clopidogrel 75mg MD 24 hours after last dose instead of LD if bleeding or bleeding concerns

21
Q

Switching from clopidogrel or prasugrel or ticagrelor

A

GIve LD (ticagrelor 180mg or prasugrel 60mg) irrespective of timing and last dose of clopidogrel

22
Q

heparin dose for ACS

A

60 units/kg bolus (max 4000 units) then 12 unit/kg/hr (max 1000 units/hr) titrated to Xa goal

During PCI: 50-100 units/kg depending on target ACT

23
Q

Morphine has a potentially significant drug-drug interaction with what class of medications?

A

P2Y12 inhibitors

potentially affects absorption and kinetics leading to delayed effect on platelets

?due to slowing of GI motility

24
Q

Role of morphine in ACS

A

Relieve ischemia, vasodilating coronary arteries and mitigating the effects of the sympathetic nervous system

25
Beta-blockers have shown what benefit and at what risk in ACS
Benefit: reduction in reinfarction and sudden cardiac death/malignant ventricular arrhythmias RIsk: hypotension and cardiogenic shock